Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Cobimetinib in BRAF Mutant Melanoma
NCT02036086Phase 2Unknown
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- Aug 2015
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib, cobimetinib in melanoma, sponsored by Sunnybrook Health Sciences Centre. Status: unknown.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02036086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036086.